Sreedevi Reddy, MD
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1437169067
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2024 at $9,319 and has fallen 65.1% since, to $3,255 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 655 payments — averaging $42.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$7K
- Echosens North America, Inc.$6K
- Novartis$1K
- Lilly USA, LLC$1K
- Rhythm Pharmaceuticals, Inc.$1K
- Abbott$873
- plus $10K from 50 others
What the payments were for
- Consulting fees$9,32234%
- Speaking & faculty fees$2,0357%
- Travel & lodging$4372%
- Food & beverage$15,68857%
- Education$870%
- Gifts$1190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FibroScan$6,300
- Korlym$5,393
- PIQRAY$1,372
- Imcivree$502
- ISTURISA$500
- REZDIFFRA$295
- Omnipod$282
- AFREZZA$264
- TWIIST$147
- CRENESSITY$139
- CeQur Simplicity$138
- INVOKANA$125
- RETEVMO$122
- JARDIANCE$119
- Minimed 530G$119
- EVENITY$118
- TEPEZZA$110
- FREESTYLE LIBRE 3$103
How this compares
$27,688 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HumatropeSomatropin | 18 | $149,390 |
| MounjaroTirzepatide | 81 | $122,018 |
| TrulicityDulaglutide | 78 | $100,481 |
| OzempicSemaglutide | 70 | $99,202 |
| JardianceEmpagliflozin | 71 | $89,359 |
| GenotropinSomatropin | 20 | $79,286 |
| ForteoTeriparatide | 14 | $70,261 |
| RybelsusSemaglutide | 29 | $35,408 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $18,371 |
| InvokanaCanagliflozin | 12 | $17,763 |
| VascepaIcosapent Ethyl | 38 | $17,594 |
| JanuviaSitagliptin Phosphate | 20 | $15,641 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $14,732 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $13,313 |
| SynthroidLevothyroxine Sodium | 142 | $13,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCHumatrope, Mounjaro, Trulicity, Forteo, Humalog | $1,238 | $446,360209 claims |
| Novo NordiskOzempic, Rybelsus | $611 | $134,61099 claims |
| Boehringer IngelheimJardiance | $417 | $89,35971 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $448 | $18,37112 claims |
| Johnson & JohnsonInvokana | $65 | $17,76312 claims |
| MerckJanuvia | $26 | $15,64120 claims |
| AbbVieSynthroid | $503 | $13,110142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $288 | $5,349458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
- Mercedes RomeroScottsdale$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.